Low miR-145 silenced by DNA methylation promotes NSCLC cell proliferation, migration and invasion by targeting mucin 1

References

• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates ofworldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893-917; PMID:21351269; http://dx.doi.org/10.1002/ijc.25516
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-49; PMID:19474385; http://dx.doi.org/10.3322/caac.20006
   PubMed Web of Science ®Google Scholar
• Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell 2012; 148:1172-87; PMID:22424228; http://dx.doi.org/10.1016/j.cell.2012.02.005
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136:215-33; PMID:19167326; http://dx.doi.org/10.1016/j.cell.2009.01.002
   PubMed Web of Science ®Google Scholar
• Kim TH, Song JY, Park H, Jeong JY, Kwon AY, Heo JH, Kang H, Kim G, An HJ. miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma. Cancer Lett 2015; 356:937-45; PMID:25444913; http://dx.doi.org/10.1016/j.canlet.2014.11.011
   PubMed Web of Science ®Google Scholar
• Dong R, Liu X, Zhang Q, Jiang Z, Li Y, Wei Y, Li Y, Yang Q, Liu J, Wei JJ, et al. miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma. Oncotarget 2014; 5:10816-29; PMID:25333261
   PubMed Web of Science ®Google Scholar
• Zhu X, Li Y, Xie C, Yin X, Liu Y, Cao Y, Fang Y, Lin X, Xu Y, Xu W, et al. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6. Int J Cancer 2014; 135:1286-96; PMID:24510775; http://dx.doi.org/10.1002/ijc.28774
   PubMed Web of Science ®Google Scholar
• Cioce M, Ganci F, Canu V, Sacconi A, Mori F, Canino C, Korita E, Casini B, Alessandrini G, Cambria A, et al. Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma. Oncogene 2014; 33:5319-31; PMID:24240684; http://dx.doi.org/10.1038/onc.2013.476
   PubMed Web of Science ®Google Scholar
• Yan X, Chen X, Liang H, Deng T, Chen W, Zhang S, Liu M, Gao X, Liu Y, Zhao C, et al. miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer. Mol Cancer 2014; 13:220; PMID:25248370; http://dx.doi.org/10.1186/1476-4598-13-220
   PubMed Web of Science ®Google Scholar
• Khan S, Ebeling MC, Zaman MS, Sikander M, Yallapu MM, Chauhan N, Yacoubian AM, Behrman SW, Zafar N, Kumar D, et al. MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer. Oncotarget 2014; 5:7599-609; PMID:25277192
   PubMedGoogle Scholar
• Kent OA, Chivukula RR, Mullendore M, Wentzel EA, Feldmann G, Lee KH, Liu S, Leach SD, Maitra A, Mendell JT. Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev 2010; 24:2754-9; PMID:21159816; http://dx.doi.org/10.1101/gad.1950610
   PubMed Web of Science ®Google Scholar
• Gits CM, van Kuijk PF, Jonkers MB, Boersma AW, Smid M, van Ijcken WF, Coindre JM, Chibon F, Verhoef C, Mathijssen RH, et al. MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR-145 and miR-451 as tumor suppressors. Int J Cancer 2014; 135:348-61; PMID:24375455; http://dx.doi.org/10.1002/ijc.28694
   PubMed Web of Science ®Google Scholar
• Feng Y, Zhu J, Ou C, Deng Z, Chen M, Huang W, Li L. MicroRNA-145 inhibits tumour growth and metastasis in colorectal cancer by targeting fascin-1. Br J Cancer 2014; 110:2300-9; PMID:24642628; http://dx.doi.org/10.1038/bjc.2014.122
   PubMed Web of Science ®Google Scholar
• Pagliuca A, Valvo C, Fabrizi E, di Martino S, Biffoni M, Runci D, Forte S, De Maria R, Ricci-Vitiani L. Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene 2013; 32:4806-13; PMID:23128394; http://dx.doi.org/10.1038/onc.2012.495
   PubMed Web of Science ®Google Scholar
• Ibrahim AF, Weirauch U, Thomas M, Grunweller A, Hartmann RK, Aigner A. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res 2011; 71:5214-24; PMID:21690566; http://dx.doi.org/10.1158/0008-5472.CAN-10-4645
   PubMed Web of Science ®Google Scholar
• Xu Q, Liu LZ, Qian X, Chen Q, Jiang Y, Li D, Lai L, Jiang BH. MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res 2012; 40:761-74; PMID:21917858; http://dx.doi.org/10.1093/nar/gkr730
   PubMed Web of Science ®Google Scholar
• Zhang H, Pu J, Qi T, Qi M, Yang C, Li S, Huang K, Zheng L, Tong Q. MicroRNA-145 inhibits the growth, invasion, metastasis and angiogenesis of neuroblastoma cells through targeting hypoxia-inducible factor 2 α. Oncogene 2014; 33:387-97; PMID:23222716; http://dx.doi.org/10.1038/onc.2012.574
   PubMed Web of Science ®Google Scholar
• Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, Elble R, Watabe K, Mo YY. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci U S A 2009; 106:3207-12; PMID:19202062; http://dx.doi.org/10.1073/pnas.0808042106
   PubMed Web of Science ®Google Scholar
• Sachdeva M, Mo YY. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 2010; 70:378-87; PMID:19996288; http://dx.doi.org/10.1158/0008-5472.CAN-09-2021
   PubMed Web of Science ®Google Scholar
• Spizzo R, Nicoloso MS, Lupini L, Lu Y, Fogarty J, Rossi S, Zagatti B, Fabbri M, Veronese A, Liu X, et al. miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-α in human breast cancer cells. Cell Death Differ 2010; 17:246-54; PMID:19730444; http://dx.doi.org/10.1038/cdd.2009.117
   PubMed Web of Science ®Google Scholar
• Gotte M, Mohr C, Koo CY, Stock C, Vaske AK, Viola M, Ibrahim SA, Peddibhotla S, Teng YH, Low JY, et al. miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness. Oncogene 2010; 29:6569-80; PMID:20818426; http://dx.doi.org/10.1038/onc.2010.386
   PubMed Web of Science ®Google Scholar
• Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M, Matsubara H. miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 2010; 127:2804-14; PMID:21351259; http://dx.doi.org/10.1002/ijc.25284
   PubMed Web of Science ®Google Scholar
• Ostenfeld MS, Bramsen JB, Lamy P, Villadsen SB, Fristrup N, Sorensen KD, Ulhoi B, Borre M, Kjems J, Dyrskjot L, et al. miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. Oncogene 2010; 29:1073-84; PMID:19915607; http://dx.doi.org/10.1038/onc.2009.395
   PubMed Web of Science ®Google Scholar
• Villadsen SB, Bramsen JB, Ostenfeld MS, Wiklund ED, Fristrup N, Gao S, Hansen TB, Jensen TI, Borre M, Orntoft TF, et al. The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer. Br J Cancer 2012; 106:366-74; PMID:22108519; http://dx.doi.org/10.1038/bjc.2011.520
   PubMed Web of Science ®Google Scholar
• Ostenfeld MS, Bramsen JB, Lamy P, Villadsen SB, Fristrup N, Sorensen KD, Ulhoi B, Borre M, Kjems J, Dyrskjot L, et al. miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. Oncogene 2010; 29:1073-84; PMID:19915607; http://dx.doi.org/10.1038/onc.2009.395
   PubMed Web of Science ®Google Scholar
• Zaman MS, Chen Y, Deng G, Shahryari V, Suh SO, Saini S, Majid S, Liu J, Khatri G, Tanaka Y, et al. The functional significance of microRNA-145 in prostate cancer. Br J Cancer 2010; 103:256-64; PMID:20588276; http://dx.doi.org/10.1038/sj.bjc.6605742
   PubMed Web of Science ®Google Scholar
• Suh SO, Chen Y, Zaman MS, Hirata H, Yamamura S, Shahryari V, Liu J, Tabatabai ZL, Kakar S, Deng G, et al. MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis 2011; 32:772-8; PMID:21349819; http://dx.doi.org/10.1093/carcin/bgr036
   PubMed Web of Science ®Google Scholar
• Gao P, Xing AY, Zhou GY, Zhang TG, Zhang JP, Gao C, Li H, Shi DB. The molecular mechanism of microRNA-145 to suppress invasion-metastasis cascade in gastric cancer. Oncogene 2013; 32:491-501; PMID:22370644; http://dx.doi.org/10.1038/onc.2012.61
   PubMed Web of Science ®Google Scholar
• Yu CC, Tsai LL, Wang ML, Yu CH, Lo WL, Chang YC, Chiou GY, Chou MY, Chiou SH. miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer. Cancer Res 2013; 73:3425-40; PMID:23548270; http://dx.doi.org/10.1158/0008-5472.CAN-12-3840
   PubMed Web of Science ®Google Scholar
• Campayo M, Navarro A, Vinolas N, Diaz T, Tejero R, Gimferrer JM, Molins L, Cabanas ML, Ramirez J, Monzo M, et al. Low miR-145 and high miR-367 are associated with unfavourable prognosis in resected nonsmall cell lung cancer. Eur Respir J 2013; 41:1172-8; PMID:22835608; http://dx.doi.org/10.1183/09031936.00048712
   PubMed Web of Science ®Google Scholar
• Cho WC, Chow AS, Au JS. MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol 2011; 8:125-31; PMID:21289483; http://dx.doi.org/10.4161/rna.8.1.14259
   PubMed Web of Science ®Google Scholar
• Cho WC, Chow AS, Au JS. Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur J Cancer 2009; 45:2197-206; PMID:19493678; http://dx.doi.org/10.1016/j.ejca.2009.04.039
   PubMed Web of Science ®Google Scholar
• Li DX, Cai HY, Wang X, Feng YL, Cai SW. Promoter methylation of Raf kinase inhibitory protein: A significant prognostic indicator for patients with gastric adenocarcinoma. Exp Ther Med 2014; 8:844-50; PMID:25120612
   PubMed Web of Science ®Google Scholar
• Di Ruscio A, Ebralidze AK, Benoukraf T, Amabile G, Goff LA, Terragni J, Figueroa ME, De Figueiredo PL, Alberich-Jorda M, Zhang P, et al. DNMT1-interacting RNAs block gene-specific DNA methylation. Nature 2013; 503:371-6; PMID:24107992; http://dx.doi.org/10.1038/nature12598
   PubMed Web of Science ®Google Scholar
• Duraisamy S, Kufe T, Ramasamy S, Kufe D. Evolution of the human MUC1 oncoprotein. Int J Oncol 2007; 31:671-7; PMID:17671696
   PubMed Web of Science ®Google Scholar
• Khodarev NN, Pitroda SP, Beckett MA, MacDermed DM, Huang L, Kufe DW, Weichselbaum RR. MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer. Cancer Res 2009; 69:2833-7; PMID:19318547; http://dx.doi.org/10.1158/0008-5472.CAN-08-4513
   PubMed Web of Science ®Google Scholar
• Kharbanda A, Rajabi H, Jin C, Tchaicha J, Kikuchi E, Wong KK, Kufe D. Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells. Clin Cancer Res 2014; 20:5423-34; PMID:25189483; http://dx.doi.org/10.1158/1078-0432.CCR-13-3168
   PubMed Web of Science ®Google Scholar